Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Viiv Healthcare UK Limited

Kyle E Parcella

John F Kadow

Kap-Sun Yeung

Piyasena Hewawasam

John A Bender

Katharine A Grant-Young

Kyle J Eastman

Ying Han

Barton W Phillips

Tao Wang

Zhongxing Zhang

B Narasimhulu Naidu

Steven R Magnuson

Zhonghua Zhang

Manoj Patel

Stephen J O'Connor

Louis Stanley Chupak

Zheng Liu

Mark George Saulnier

Zhiwei Yin

Eric P Gillis

Kevin M Peese

Alan Xiangdong Wang

David Bertil Frennesson

Uday R Khire

Paul Michael Scola

Jacques P Dumas

Makonen Belema

David R Langley

Li-Qiang Sun

Gan Wang

Prasanna Sivaprakasam

Wendy Lee

Eric Mull

Tatiana Shelekhin

David Gunn

Xin Ma

Brett R Beno

Andrew Nickel

Julie A Dixon

Jason S Newcom

Zhenqiu Hong

Brent Chandler

Harold C E Kluender

Richard Pracitto

Furahi Achebe

Martin Michels

Yamin Wang

Lei Wang

Kristen M Allegue

Ramkumar Rajamani

Timothy P Connolly

Mario Lobell

Yong Tu

Michael S Bowsher

Ningning Xu

Zhaoxing Meng

Christiana I Iwuagwu

Juliang Zhu

Jennifer Burke

Christiana Iwuagwu

Shihong Ying

Tindy Li

Andrea McClure

Tandy Li

Harold Kluender

Zhen Liu

David Cantin

Derek Lowe

Frederick Ehrgott

Davidb Frennesson

Narasimhulu B Naidu

Julie Dixon

Kristen Allegue

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: 

Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C

Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), Ris selected from hydrogen, alkyl, or cycloalkyl; Ris selected from tetrahydroisoquinolinyl and is substituted with 1 Rsubstituent and also with 0-3 halo or alkyl substituents; Ris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ris selected from alkyl or haloalkyl; Ris alkyl; Ris selected from Ar, (Ar)alkyl, (chromanyl)alkyl, cyanocycloalkyl or (dihydrobenzodioxinyl)alkyl; and Aris phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl. 

Substituted pyridines as inhibitors of human immunodeficiency virus replication

Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Furopyridine compounds for the treatment of hepatitis C

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Fused furans for the treatment of hepatitis C

Cyano containing azabenzofuran compounds for the treatment of hepatitis C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer. 

Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases

Growing community of inventors

Wallingford, CT, United States of America

Kyle E Parcella